Close Menu

NEW YORK (GenomeWeb) – Albany Molecular Research (AMRI) announced it has obtained a non-exclusive license for CRISPR/Cas9 technology from the Broad Institute.

The contract research organization said in a statement that CRISPR offered "significant utility" for pharmaceutical research and development, especially drug target assessment, in vitro model development, and optimization. AMRI reported that it has already used CRISPR/Cas9 in both customer and internal R&D projects.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.